Immune Design (IMDZ) Upgraded to "Buy" by Zacks Investment Research

Lester Mason
January 13, 2018

Vetr raised shares of United Parcel Service from a "sell" rating to a "hold" rating and set a $116.85 price objective on the stock in a research report on Tuesday, December 26th. (NASDAQ:IMDZ) earned "Buy" rating by Cowen & Co on Tuesday, June 6. The business had revenue of $0.52 million for the quarter, compared to analyst estimates of $0.62 million. analysts expect that Immune Design will post -1.89 EPS for the current year. (NASDAQ:IMDZ) shares with value of $8,282 were sold by ter Meulen Jan Henrik. Proquest Associates Iv Llc sold 549,440 shares as the company's stock rose 32.73% with the market. Out of rating recommendations 2 have given the stock a Buy while 2 recommend the stock as Outperform. The stock of Immune Design Corp. Its quick ratio for most recent quarter is 1.3 along with current ratio for most recent quarter of 1.6. (TILE) stake by 0.73% reported in 2017Q3 SEC filing.

On Track Innovations (NASDAQ:OTIV)'s shares slipped -2.72% in the past week and soared 34.78% in the last 4 weeks, historically the stock illustrate that its six months performance stands at 7.52% while its year to date performance is at 5.15%. The company has a market cap of $169.1 Million. California State Teachers Retirement System now owns 30,174 shares of the biotechnology company's stock worth $294,000 after purchasing an additional 2,300 shares during the last quarter. The shares were purchased at an average price of $3.90 per share, with a total value of $78,000.00. PIMCO Corporate & Income Strategy Fund (PCN) has risen 19.51% since January 12, 2017 and is uptrending. The firm now has a $4.25 price target on the biotechnology company's stock.

Immune Design Corp. (IMDZ) has so far tried and showed success to beat the consensus-estimated -$0.63, with their earning staying at -$0.52 per share. It has underperformed by 37.85% the S&P500.

Of those holders, 33 had increased positions amounting to 2.16 million shares, 29 had decreased positions amounting to 1.24 million shares, and 10 holders have a held position accounting for 10.7 million shares. The firm has a market cap of $173.01, a P/E ratio of -1.69 and a beta of 2.36. (NASDAQ:IMDZ) is performing. Immune Design Corp. has had 16 insider trades in the last 3 months, including 11 open market buys and 5 sells. 13 funds opened positions while 20 raised stakes. Art Advsr Ltd Co reported 19,230 shares.

Additionally on 9/15/17 RBC Capital "Initiates Coverage On" Immune Design CS (NASDAQ:IMDZ) to Outperform setting price target at $20 and on 8/10/16 Jefferies "Maintained" the stock to Buy at $17. (NASDAQ:IMDZ) or 3,517 shares. Doheny Asset Ca has invested 2.91% in Immune Design Corp. The shares now trade at $3.65 and have been able to report a change of -7.59% over the past one week. Focused Wealth Mngmt invested in 0.05% or 13,065 shares. Financial Bank Of New York Mellon holds 0% or 72,609 shares in its portfolio. Meeder Asset Mngmt Inc accumulated 159 shares. Alliancebernstein Limited Partnership holds 0% or 12,100 shares. (NASDAQ:IMDZ) for 14,822 shares. Ameritas Inv Prtn accumulated 874 shares or 0% of the stock. Balyasny Asset Limited Com has 10,537 shares. About 53.35M shares traded or 33.89% up from the average. Credit Suisse Ag accumulated 11,241 shares.

Since August 1, 2017, it had 2 buys, and 6 sales for $21.80 million activity. Also, Director Lewis W. Coleman sold 10,000 shares of the stock in a transaction on Thursday, December 22nd. Another trade for 2.68M shares valued at $10.99M was made by COLUMN GROUP L P on Friday, October 27. Following the sale, the chief executive officer now directly owns 114,560 shares in the company, valued at approximately $477,715.20. Jpmorgan Alerian (AMJ) was reduced too. (NASDAQ:MU), 35 have Buy rating, 0 Sell and 7 Hold. Therefore 83% are positive.

According to Zacks, "Immune Design's primary candidates, CMB305 and G100, are being evaluated for solid tumor, and merkel cell carcinoma (MCC) and sarcoma, respectively". The stock has "Buy" rating by Jefferies on Monday, September 4. The rating was downgraded by Macquarie Research to "Underperform" on Monday, April 24. Bank of America Corp DE now owns 15,246 shares of the biotechnology company's stock worth $104,000 after purchasing an additional 8,418 shares in the last quarter. The stock of Barclays PLC (NYSE:BCS) earned "Sell" rating by Goldman Sachs on Friday, May 5. Wells Fargo has "Market Perform" rating and $10 target. The institutional investor held 1.41 million shares of the major pharmaceuticals company at the end of 2017Q3, valued at $14.63 million, down from 1.96M at the end of the previous reported quarter.

Other reports by Iphone Fresh

Discuss This Article